Analogues of GLP-1

Details Analogues of GLP-1 Analogues of GLP-1

2011-07-12

2011-07-12

Lukton, David (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C530S308000, C514S021300

Reexamination Certificate

active

07977455

ABSTRACT:
The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.

REFERENCES:
patent: 5512549 (1996-04-01), Chen et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5705483 (1998-01-01), Galloway et al.
patent: 6214547 (2001-04-01), Kjeldsen et al.
patent: 6410513 (2002-06-01), Galloway et al.
patent: 6458924 (2002-10-01), Knudsen et al.
patent: 6620910 (2003-09-01), Calas et al.
patent: 6720407 (2004-04-01), Hughes et al.
patent: 6903186 (2005-06-01), Dong et al.
patent: 2 352 573 (2000-06-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 699 686 (1996-03-01), None
patent: 0 699 686 (1996-03-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 733 644 (1996-09-01), None
patent: 0 869 135 (1998-10-01), None
patent: WO 87/06941 (1987-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 97/29180 (1997-08-01), None
patent: WO 98/03547 (1998-01-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/19698 (1998-05-01), None
patent: 99/43705 (1999-09-01), None
patent: 00/34331 (2000-06-01), None
patent: 01/35988 (2001-05-01), None
Gutniak, Mark, et al.; “Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus”; 1992; The New England Journal of Medicine; vol. 326 No. 20; pp. 1316-1322.
Mentlein,:R., et al; “Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, Gluengon-like peptide-1(7-36) amide, peptide histidine rnethionine and is responsible for their degradation in human serum”; 1993; Biochem; vol. 214; pp. 829-835.
Nauck, M. A., et al.; “Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide))in patients with NIDDM”; 1996; Diabetologia; vol. 82: 2; pp. 1546-1553.
Parker, J. C., et al.; “Structure-function analysis of a series of glucagon-like peptide-1 analogs”; 1998: Peptide Res; vol. 52: 5; pp. 398-409; XP-000788444.
Rachman, J., et al.; “Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1)in subjects with NIDDM”; 1997; Diabetologia; vol. 40; pp. 205-211.
Suzuki, S., et al.; “Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptides of Glucagon-Like Peptide-1 on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas”; 1989; Endocrinology; vol. 125: 6; pp. 3109-3114.
Thorens, Bernard, et al.; “Glucagon-Like Peptide- and the Control of Insulin Secretion in the Normal State and in NIDDM”; 1993; Diabetes; vol. 42: pp. 1219-1225.
Thorens, Bernard, et al.; “Structure and Function of the Glucagon-Like Peptide-1 Receptor”; 1996; Handbook of Experimental Pharmacology; vol. 123; pp. 255-273.
Todd, J. F., et al.; “Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus”; 1997; European Journal of Clinical Investigation; vol. 27; pp. 533-536.
Ahren, Bo, et al.; “Effects of Glucagon-Like Peptide-1 on Islet. Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus”; 1997; Journal of Clinical Endocrinology and Metabolism; vol. 82: 2; pp. 473-478.
Deacon, C-F., et al.; “Dipeptidyl. peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity”: 1998; Diabetologia; vol. 41; pp. 271-278.
Deacon, C. F., et al.; “Dipeptidyl Peptidase lV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig”; 1998; Diabetes; vol. 47; pp. 764-769.
Adelhorst, K. et al., “Structure-activity studies of glucagon-like peptide-1,” J. Biological Chemistry, 1994, 269(9):6275-6278.
Bray, G. A. et al., “Current and potential drugs for treatment of obesity”, Endocrine Reviews, 1999, 20:805-875.
Kordik, C. P. et al., “Pharmacological treatment of obesity: therapeutic strategies”, J. Med. Chem., 1999, 42:181-201.
Mojsov, S. “Structural requirements for biological activity of glucagon-like peptide 1,” Int. J. Pep. Prot. Res., 1992, 40:333-343.
Ritzel, U. et al., “A synthetic glucagon-like peptide-1 analog with improved plasma stability,” J. Endocrinology, 1998, 159:93-102.

Affiliated with

Also associated with

Rating

Analogues of GLP-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Analogues of GLP-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogues of GLP-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2733160